ResearchPod Summary
Since the 2009 report of a cure for HIV in a patient receiving a CCR5Δ32 stem cell transplant, the field has struggled to replicate this success. While antiretroviral therapy (ART) effectively suppresses viral replication, it does not eliminate the virus. HIV persists in a latent state within long-lived CD4+ T cells and various tissue reservoirs, such as the gastrointestinal tract and lymph nodes. These reservoirs remain the primary barrier to a cure, as they can trigger viral rebound if ART is discontinued.
Research over the last decade has revealed that HIV persistence is driven by multiple factors. Latency is established very early in infection, and the virus can persist in diverse T cell subsets, including naive and memory cells. Furthermore, latently infected cells can undergo clonal expansion, allowing the virus to persist even without active replication. While the role of residual viral replication on ART remains debated, it is clear that the virus is sequestered in anatomical sanctuaries, such as B cell follicles, where immune surveillance by cytotoxic CD8+ T cells is limited.
Efforts to achieve a cure are generally categorized into three approaches: targeting the viral replication cycle, enhancing the HIV-specific immune response, and modulating the immune system. Latency-reversing agents (LRAs) aim to 'shock' the virus out of latency to make infected cells visible to the immune system, but they have yet to demonstrate a significant reduction in the total reservoir size. Other strategies, such as gene editing (e.g., CRISPR/Cas-9), broadly neutralizing antibodies (bNAbs), and therapeutic vaccines, are being evaluated to either render cells resistant to infection or to actively clear infected cells. Immune checkpoint blockers, while promising for enhancing T cell function, carry significant risks of immune-related adverse events.
Given the complexity of the viral reservoir, a combination approach is likely necessary to achieve remission. Future research must prioritize the development of more potent and less toxic interventions, as well as reliable biomarkers to predict clinical outcomes after treatment interruption. Furthermore, it is critical that cure research becomes more inclusive of diverse populations, particularly in low- and middle-income countries where the burden of HIV is highest.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.